Shots:
- The P-II ELARA study involves assessing the efficacy and safety of Kymriah in adult patients with r/r FL across 12 countries in 30 sites globally
- At the interim analysis, the study met its 1EPs of CRR, as assessed by IRC. The company will include the results in regulatory submissions, with anticipated filing to the US FDA in 2021, and then in EU, while the results will be presented at an upcoming medical meeting
- Kymriah has received FDA’s RMAT designation in r/r FL based on preliminary ELARA trial findings, reflecting the unmet need for additional treatment options for FL. The Therapy was developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania
Click here to read full press release/ article | Ref: Novartis | Image: Behance
Related News: Novartis’ Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults
